Curriculum Vitae Adam J. Olszewski, MD Associate Professor of Medicine, Alpert Medical School of Brown University Address: Lifespan Cancer Institute at Rhode Island Hospital George Building, Rm. 353 593 Eddy St, Providence, RI 02903 Tel: (401) 429 3151 Fax: (401) 444 8918 E-mail: [email protected] ORCID 0000-0002-6472-6658 Language fluency: Spanish, French, Polish, Russian Research profile: https://vivo.brown.edu/display/aolszews Employment Rhode Island Hospital 02/2016 – present • Clinical Hematologist/Oncologist and researcher Alpert Medical School of Brown University • Assistant Professor of Medicine 08/2010 – 07/2019 • Associate Professor of Medicine 08/2019 – The Cancer Center at Memorial Hospital of Rhode Island 08/2010 – 02/2016 • Clinical Oncologist / Hematologist • Cancer Committee Chair Kent County Hospital, Warwick, RI 2007 – 2010 • Clinical Oncologist / Hematologist • Physician Director, Outpatient Infusion Services University Medical Group, Providence, RI 2006 – 2010 • Clinical Oncologist / Hematologist Education Hematology/Oncology Fellowship 07/2003 – 06/2006 St. Luke’s-Roosevelt Hospital Center, New York Internal Medicine Residency 07/2000 – 06/2003 St. Luke’s-Roosevelt Hospital Center, New York Teaching affiliate of College of Physicians and Surgeons of Columbia University The Medical University of Warsaw, Poland 09/1993 – 06/1999 MD degree 06/1999 Licensure and certification ABIM Board Certified: Hematology 11/2007 – present ABIM Board Certified: Medical Oncology 11/2006 – present ABIM Board Certified: Internal Medicine 08/2003 – present MD License: Rhode Island 11/2005 – active Professional affiliations and leadership functions American Society of Clinical Oncology, member American Society of Hematology, member Alpha Omega Alpha Honor Medical Society, member Adam J. Olszewski – CV Chair, Head and Neck Committee 2015 – 2016 Co-chair, Humanities and Outcomes Committee 2016 – present Brown University Oncology Group (BrUOG) American Society of Clinical Oncology/American Board of Internal Medicine Hematologic Malignancies Test Materials Development Subcommittee 2018 – present Brown University Oncology Group (BrUOG) Member, Data Safety Monitoring Board 2012 – present American Society of Clinical Oncology, Scientific Program Committee Member, Cancer Prevention/Epidemiology Track 2013 – 2016 Track leader 2015 – 2016 American Society of Clinical Oncology, Cancer Education Program Member, Cancer Prevention/Epidemiology Track 2015 – 2016 Chair, Cancer Committee, Memorial Hospital of Rhode Island 2013 – 2016 Member, Institutional Review Board, MHRI 2011 – 2016 Member, Pharmacy and Therapeutics Committee, MHRI 2011 – 2016 Chair, Institutional Review Board, Kent Hospital, Warwick, RI 2007 – 2010 Member, Breast Health Center Leadership Group, Kent Hospital 2009 – 2010 Honors and awards Academic Proficiency Award, years 2 through 6 1994 – 1999 The Medical University of Warsaw, Poland W.I.S.E. (Worldwide Insitute Supporting 1999 Exchange) Scholarship, Worcester, MA Award for Outstanding Excellence in Primary Care 2003 St. Luke’s-Roosevelt Hospital Center, New York Chief Fellow Appointment 2005 St. Luke’s-Roosevelt Hospital Center, New York Teaching Achievement Award for Outstanding Teaching 2014 Internal Medicine Residency Program, Memorial Hospital of Rhode Island, Alpert Medical School of Brown University American Society of Hematology 2015 Scholar Award 2015 (Clinical Junior Faculty) 2015 Beckwith Family Teaching Award for outstanding teaching 2015 Alpert Medical School of Brown University Dean's Excellence in Teaching Award 2015 Alpert Medical School of Brown University American Cancer Society Research Scholar Award 2015 Teaching Achievement Award for Outstanding Teaching 2016 Internal Medicine Residency Program, Memorial Hospital of Rhode Island, Alpert Medical School of Brown University Excellence in Teaching Award 2019 Hematology-Oncology Fellowship, Alpert Medical School of Brown University Teaching experience Practice-Based Learning 2011 – 2016 Warren Alpert Medical School of Brown University Clinical Teaching Rounds 2011 – 2013 Memorial Hospital of Rhode Island 2 Adam J. Olszewski – CV Career Mentorship, Medical Residents PGY1-PGY3 2010 – present Memorial Hospital of Rhode Island Research Mentorship, Brown University Medical Students 2012 – present Internal Medicine Conference Lectures 2011 – present BIOL3672: IMS-IV: Integrated Hematology Course, Faculty 2017 – 2020 Peer-reviewed publications (reverse chronological order) h-index: 15 PubMed bibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/adam.olszewski.1/bibliography/40055989/public/ 1. Olszewski AJ, Butera JN, Reagan JL, Castillo JJ. Outcomes of bendamustine- or cyclophosphamide- based first-line chemotherapy in older patients with indolent B-cell lymphoma. Am J Hematol. 2019 Dec 17;. doi: 10.1002/ajh.25707. [Epub ahead of print] PubMed PMID: 31849108. 2. Dusetzina SB, Huskamp HA, Jazowski SA, Winn AN, Wood WA, Olszewski A, Basch E, Keating NL. Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients with Blood Cancers. J Natl Cancer Inst. 2019 Dec 27;. doi: 10.1093/jnci/djz243. [Epub ahead of print] PubMed PMID: 31883008. 3. Olszewski AJ, Barth PM, Reagan JL. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma. Cancer Med. 2019 Nov;8(16):6945-6954. doi: 10.1002/cam4.2591. PubMed PMID: 31566898. 4. Ayers EC, Li S, Medeiros LJ, Bond DA, Maddocks KJ, Torka P, Mier Hicks A, Curry M, Wagner- Johnston ND, Karmali R, Behdad A, Fakhri B, Kahl BS, Churnetski MC, Cohen JB, Reddy NM, Modi D, Ramchandren R, Howlett C, Leslie LA, Cytryn S, Diefenbach CS, Faramand R, Chavez JC, Olszewski AJ, Liu Y, Barta SK, Mukhija D, Hill BT, Ma H, Amengual JE, Nathan S, Assouline SE, Orellana-Noia VM, Portell CA, Chandar A, David KA, Giri A, Hess BT, Landsburg DJ. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer. 2019. Epub 2019/10/01. doi: 10.1002/cncr.32526. PubMed PMID: 31568564. 5. Decker DP, Egan PC, Zayac AS, Treaba DO, Olszewski AJ. Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma. Leuk Lymphoma. 2020 Jan;61(1):198-201. doi: 10.1080/10428194.2019.1654097. PubMed PMID: 31432717. 6. Ollila TA, Reagan JL, Olszewski AJ. Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base. Leuk Lymphoma. 2019 Dec;60(14):3426-3433. doi: 10.1080/10428194.2019.1639166. PubMed PMID: 31287335. 7. Orcutt X, Barth P, Olszewski AJ. Prognostic significance of upfront radiation therapy in patients with multiple myeloma. Am J Hematol. 2019 Jul;94(7):E190-E194. doi.org/10.1002/ajh.25492 PMID: 31006894 8. Olszewski AJ, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera JN, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka PM. Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. Br J Haematol. 2019 Aug;186(3):e31-e35. doi: 10.1111/bjh.15861. PMID: 30859554. 9. Fallah J, Olszewski AJ. Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology. 2019;24(1):378-86. PMID: 30885066 10. Ollila TA, Sahin I, Olszewski AJ. Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma. Onco Targets Ther. 2019;12:1085-94. doi: 10.2147/OTT.S165615. PMID: 30799938 11. Barth P, Castillo JJ, Olszewski AJ. Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study. Cancer. 2019;125(4):550-8. doi: 10.1002/cncr.31853. PMID: 30452087. 12. Olszewski AJ, Castillo JJ. Ibrutinib and Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med. 2018;379(20):1973-4. doi: 10.1056/NEJMc1809505. PubMed PMID: 30439672. 3 Adam J. Olszewski – CV 13. Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM. Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis. Blood. 2018;132(19):2053-66. doi: 10.1182/blood-2018-05- 848408. PubMed PMID: 30213875. 14. Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ. Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries. J Clin Oncol. 2018;36(28):2879-86. doi: 10.1200/JCO.2018.77.8894. PMID: 30113885 15. LeBlanc TW, Egan PC, Olszewski AJ. Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia. Blood. 2018 Aug 16;132(7):717-726. doi: 10.1182/blood-2018-03- 842575. 16. Ollila TA, Olszewski AJ. Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. Curr Treat Options Oncol. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. 17. Ollila TA, Olszewski AJ. Radiation therapy in primary testicular lymphoma: does practice match the standard of care? Leuk Lymphoma. 2019;60(2):523-6. doi: 10.1080/10428194.2018.1480776. 18. Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol. 2018 May;181(4):495-504. doi: 10.1111/bjh.15224. 19. Olszewski AJ, Zullo AR, Nering CR, Huynh JP. Use of Charity Financial Assistance for Novel Oral